Short-, mid-, and long-term efficacy of deucravacitinib versus biologics and nonbiologics for plaque psoriasis: A network meta-analysis
Introduction Deucravacitinib, a newly approved oral medication for the treatment of patients
with moderate to severe plaque psoriasis, demonstrated efficacy versus apremilast and
placebo in two phase 3 randomized controlled trials (RCTs). A systematic review and
network meta-analysis (NMA) indirectly compared deucravacitinib with other relevant
systemic biologic/nonbiologic treatments. Methods Online databases were searched for
RCTs published through October 2021. Eligible studies were head-to-head comparisons …
with moderate to severe plaque psoriasis, demonstrated efficacy versus apremilast and
placebo in two phase 3 randomized controlled trials (RCTs). A systematic review and
network meta-analysis (NMA) indirectly compared deucravacitinib with other relevant
systemic biologic/nonbiologic treatments. Methods Online databases were searched for
RCTs published through October 2021. Eligible studies were head-to-head comparisons …
以上显示的是最相近的搜索结果。 查看全部搜索结果